Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Bohao Zheng
Observed name:
Zheng, Bohao
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Shanghai Xuhui Central Hospital,
Zhongshan Hospital
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Shanghai Xuhui Central Hospital,
Zhongshan Hospital
ORCID:
0009-0007-0288-3299
Observed ORCID:
0009-0007-0288-3299
OpenAlex ID:
A5123480914
A phase II, exploratory trial of cadonilimab (AK104) plus gemcitabine-cisplatin (GC) as a conversion therapy for patients (pts) with unresectable or systemic treatment–failed biliary tract cancer (BTC).
2026
·
Hobao Liu
, Yan Wang
, et al.
·
Journal of Clinical Oncology
·
1
Phosphorylation destabilizes Per3 to promote gallbladder carcinoma
2026
·
Kun Fan
, Xi Cheng
, et al.
·
Experimental Cell Research
Data from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Figure S8 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Information Table 2 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Figure S4 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Information Table 1 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Figure S9 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Information Table 4 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Figure S5 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Figure S3 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Information Table 3 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Figure S10 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Information Table 5 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Figure S1 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Figure S2 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Figure S7 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Supplementary Figure S6 from Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma
2026
·
Nianxin Zhou
, Fan Fei
, et al.
Noninvasive detection and prognostic stratification of biliary tract cancer using cell-free DNA fragmentomics: a model development and validation study
2026
·
Jiwen Wang
, Xiaojian Ni
, et al.
·
Molecular Biomedicine
PDF
Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair
2026
·
Ni, Xiaojian
, Li, Min
, et al.
·
Figshare
Show more works
View as search
Works count:
27
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type